| Objective:Evaluat the clinical efficacy and safety for early application of recombinant human brain natriuretic peptide in patients with ST-segment elevation myocardial infarction following acute heart failure.Methods:1.A total of 115 patients as a research object were collected,who suffered from acute ST-segment elevation myocardial infarction following heart failure and hospitalized in CCU ward of NingXia Medical University general hospital from November 2017 to October 2019.All patients were given dual antiplatelet,lipid regulation stabilizes plaques,expansion of coronary artery,diuresis and other drug treatments.According to whether or not to use the recombinant human brain natriuretic peptide,the patients were divided into the experimental group(55 cases)and the control group(60 cases).2.These two groups were analyzed about the changes of urine volume,heart rate and blood pressure before and after treatment for patients;Compared with Plasma NT-proBNP level,heart failure symptoms and cardiac function(LVEF,SV,LVEDV,LVESV)for the patients before and after treatment.Analyzed the changes of electrolyte and renal function for patients before and after treatment.The cases about these two groups were recorded including the drug-related adverse events and the length of hospital stay for CCU.3.SPSS23.0 statistical software was used for analysis,P<0.05 means the difference is statistically significant.Results:1.The patients' Cardiac function with the total efficiency of 89.09% and 73.33% in both group,which is the experimental group higher than the control group.(P<0.05).2.After treatment,The patients' urine volume increased after 24 hours' treatment in both groups,there was more obvious increase of the patients' urine volume in the experimental group(P<0.05),And there was more obvious decrease of the patients' serum creatinine in the experimental group(P<0.05).There was no significant fluctuation of electrolyte(serum K+,Na+)in the two groups(P>0.05).3.After treatment,the patients' heart rate decreased in both groups,and there was no difference in the decrease level of heart rate and blood pressure(P>0.05).4.Compared with the control group,the patients' left ventricular function and stroke volume improved significantly,the patients' end diastolic volume of left ventricle? end-systolic volume of left ventricle and plasma NT-proBNP decreased obviously in the experimental group(P<0.05).5.After treatment,the length of hospital stay for CCU for the patients in the experimental group was shorter than that in the control group(P<0.05),and there were few hypotension and headache-related adverse reactions for the patients,which means the therapeutic schedule is safe and reliable.Conclusion:Combined with the conventional treatment,the addition of rhBNP in the treatment can significantly improve symptoms and sign of heart failure for the patients who suffered from ST-segment elevation myocardial infarction following acute heart failure,Meanwhile,there is no risk of electrolyte disturbance.Efficacy is relatively safe. |
PDF Full Text Request